Saturday, December 3, 2022


Biotechnology News Magazine

US T-Cell Leukemia Market and Competitive Landscape – 2022

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

The “US T-Cell Leukemia Market and Competitive Landscape – 2022” report has been added to’s offering.

The report US T-Cell Leukemia Market and Competitive Landscape Highlights – 2022, provides comprehensive insights into T-Cell Leukemia pipeline products, T-Cell Leukemia epidemiology, T-Cell Leukemia market valuations and forecast, T-Cell Leukemia drugs sales and competitive landscape in the US.

The research is classified into seven sections – T-Cell Leukemia treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.

Research Scope:

  • T-Cell Leukemia pipeline: Find out the products in clinical trials for the treatment of T-Cell Leukemia by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
  • T-Cell Leukemia epidemiology: Find out the number of patients diagnosed (prevalence) with T-Cell Leukemia in the US
  • T-Cell Leukemia drugs: Identify key products marketed and prescribed for T-Cell Leukemia in the US, including trade name, molecule name, and company
  • T-Cell Leukemia drugs sales: Find out the sales revenues of T-Cell Leukemia drugs in the US
  • T-Cell Leukemia market valuations: Find out the market size for T-Cell Leukemia drugs in 2021 in the US. Find out how the market advanced from 2019 and forecast to 2027
  • T-Cell Leukemia drugs market share: Find out the market shares for key T-Cell Leukemia drugs in the US

Benefits of this Research:

The research helps executives to

  • Support monitoring and reporting national T-Cell Leukemia market analysis and sales trends
  • Track competitor drugs sales and market share in the US T-Cell Leukemia market
  • Track competitive developments in T-Cell Leukemia market and present key issues and learnings
  • Synthesize insights for T-Cell Leukemia market and products to drive business performance
  • Answer key business questions about the T-Cell Leukemia market
  • Evaluate commercial market opportunity assessment, positioning, and segmentation for T-Cell Leukemia products
  • Supports decision making in R&D to long term marketing strategies

Key Topics Covered:

1) T-Cell Leukemia Treatments

2) T-Cell Leukemia Pipeline

3) US T-Cell Leukemia Epidemiology

4) Marketed Drugs for T-Cell Leukemia in US

5) US T-Cell Leukemia Market Size and Forecast

6) US T-Cell Leukemia Products Sales and Forecast

7) US T-Cell Leukemia Market Competitive Landscape

8) Methodology

9) Contact us

For more information about this report visit here.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine